Recent advances in the medicinal chemistry of α-aminoboronic acids, amine-carboxyboranes and their derivatives

被引:29
作者
Dembitsky, VM [1 ]
Quntar, AA [1 ]
Srebnik, M [1 ]
机构
[1] Hebrew Univ Jerusalem, Sch Pharm, Dept Med Chem & Nat Prod, IL-91120 Jerusalem, Israel
关键词
D O I
10.2174/1389557043403125
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
This article describes recent developments in the synthesis and biological activity of alpha-aminoboronic acids, amine-carboxyboranes and their derivatives as potential therapeutic agents. alpha-Amino acid analogues are of considerable interest as inhibitors of enzymes involved in amino acid and peptide metabolism. In particular, alpha-amino alkylphosphonic acids and alpha-amino alkylboronic acids, in which the carboxyl group of amino acids is replaced by a phosphonic acid or boronic acid function, respectively, constitute a unique class of amino acid mimics from which a number of potent enzyme inhibitors have been synthesized. The inhibitory activity mainly stems from the fact that the tetrahedral phosphonic moiety or the tetrahedral adduct of electrophilic boronic acid is a good mimic of the putative tetrahedral transition state or intermediate encountered in the enzymatic hydrolysis or formation of peptides. Since the peptide hydrolysis and formation invariably involves the tetrahedral high energy species in the course of the reaction, these amino acid mimics serve as a general key element for inhibitors of a broad spectrum of proteases and peptide ligases. Serine-protease inhibitors provide promising compounds having a P site binding moiety and a boronic acid chelating moiety. The compounds have been shown to have high inhibitory activity.
引用
收藏
页码:1001 / 1018
页数:18
相关论文
共 85 条
[1]  
Adams J, 2003, EXPERT OPIN THER PAT, V13, P45, DOI 10.1517/eotp.13.1.45.20919
[2]   Proteasome inhibition: a novel approach to cancer therapy [J].
Adams, J .
TRENDS IN MOLECULAR MEDICINE, 2002, 8 (04) :S49-S54
[3]   Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer [J].
Adams, J .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2002, 6 (04) :493-500
[4]   Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids [J].
Adams, J ;
Behnke, M ;
Chen, SW ;
Cruickshank, AA ;
Dick, LR ;
Grenier, L ;
Klunder, JM ;
Ma, YT ;
Plamondon, L ;
Stein, RL .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (04) :333-338
[5]   Bortezomib, a proteasome inhibitor, in cancer therapy: from concept to clinic [J].
Albanell, J ;
Adams, J .
DRUGS OF THE FUTURE, 2002, 27 (11) :1079-1092
[6]   Glutathione-like tripeptides as inhibitors of glutathionyispermidine synthetase. Part 1: Substitution of the glycine carboxylic acid group [J].
Amssons, K ;
Oza, SL ;
Ravaschino, E ;
Yamani, A ;
Lambeir, AM ;
Rajan, P ;
Bal, G ;
Rodriguez, JB ;
Fairlamb, AH ;
Augustyns, K ;
Haemers, A .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (18) :2553-2556
[7]   Trypanothione as a target in the design of antitrypanosomal and antileishmanial agents [J].
Augustyns, K ;
Amssoms, K ;
Yamani, A ;
Rajan, PK ;
Haemers, A .
CURRENT PHARMACEUTICAL DESIGN, 2001, 7 (12) :1117-1141
[8]   Ethanol withdrawal induced CYP2E1 degradation in vivo, blocked by proteasomal inhibitor PS-341 [J].
Bardag-Gorce, F ;
Li, J ;
French, BA ;
French, SW .
FREE RADICAL BIOLOGY AND MEDICINE, 2002, 32 (01) :17-21
[9]   Synthesis of the first amine-dicarboxyboranes and their derivatives [J].
Berente, Z ;
Gyori, B .
CHEMICAL COMMUNICATIONS, 1997, (18) :1799-1800
[10]   SERINE PROTEASE MECHANISM - STRUCTURE OF AN INHIBITORY COMPLEX OF ALPHA-LYTIC PROTEASE AND A TIGHTLY BOUND PEPTIDE BORONIC ACID [J].
BONE, R ;
SHENVI, AB ;
KETTNER, CA ;
AGARD, DA .
BIOCHEMISTRY, 1987, 26 (24) :7609-7614